{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-21-000031","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2021-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.938506+00:00","generated_at":"2026-06-28T15:28:33.349158+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vertex Q3 revenue $1.98B (+29% YoY); raises FY2021 guidance to $7.4-7.5B","bullets":["Product revenues of $1.984B (+29% YoY); GAAP diluted EPS $3.28, Non-GAAP $3.56.","Raised FY2021 product revenue guidance to $7.4-7.5B from prior $7.2-7.4B.","TRIKAFTA/KAFTRIO net revenues $1.556B, up 62% YoY from $960M.","Pipeline: VX-880 T1D positive data (1st patient); VX-147 Phase 2 results Q4; VX-548 data Q1 2022.","CTX001 target enrollment achieved in TDT and SCD trials; regulatory submissions planned late 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-21-000031","json":"https://secwatch.observer/filing/0000875320-21-000031.json","markdown":"https://secwatch.observer/filing/0000875320-21-000031.md","text":"https://secwatch.observer/filing/0000875320-21-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000031/0000875320-21-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532021000031/vrtx-20211102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:28:33.349158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}